Department of Health Services Logo

 

Wisconsin Department of Health Services

If You Have Complaints about Wisconsin Health Care

Information about Division of Quality Assurance (DQA)

Provider Types Regulated by DQA

DQA Listservs

Provider Search

Provider Training

DQA Numbered Memos

DHS Forms

Construction/
Remodeling of Health Care Facilities

WI Nurse Aide Training and Registry Info

Caregiver Program/ Background Checks

WI Adult Programs Caregiver Misconduct Registry

Statewide Variance of Chapters HFS 124 and HFS 83, Wisconsin Administrative Code, Mantoux Tuberculin Skin Test
***Effective Immediately***

PDF Version of BQA 06-009 (PDF 34 KB)

To: Hospitals HOSP - 07, Community Based Residential Facilities
      CBRF - 05 - OBSOLETED by 09-007 

Date: June 6, 2006 -- DDES-BQA 06-009

FROM: Jan Eakins, Section Chief, Provider Regulation and Quality Improvement

Via: Otis Woods, Director, Bureau of Quality Assurance

The purpose of this statewide variance is to provide an alternative test for the identification of tuberculosis infection.

Background

The state rules governing the Mantoux Skin Test are found in Chapters HFS 124 and 83.

Chapter HFS 124 Hospitals

HFS 124.07(2)(c) states: A Mantoux tuberculin skin test consisting of 5 tuberculin units (TU) of purified protein derivative (PPD) and, if necessary, a chest roentgenogram to determine whether disease is present, unless medically contraindicated. Persons with positive findings shall be referred to a physician for evaluation.

Chapter HFS 83 Community Based Residential Facilities

HFS 83.33(2)(g)(1)(b) states: The screening for communicable disease shall include a tuberculin skin test using the Mantoux 5TU PPD test and a visual screening for other clinically apparent communicable diseases.

On May 2, 2005 The Federal Drug Administration (FDA) approved the QuantiFERON -TB GOLD blood test as another method to screen for active tuberculosis (TB) or latent tuberculosis infection (LTBI). It is a whole blood test and does not require a return visit to determine results. On December 16, 2005, CDC published "Guidelines for Using the QuantiFERON®-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States" MMWR, Recommendations and Reports, 54(RR15);49-54 and it can be found at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5415a4.htm

Action

A statewide variance, from the two state rules listed above, is being granted to include QuantiFERON -TB GOLD as an alternative test for Tuberculosis.

The use of this variance must not jeopardize the health, safety or welfare of any patient or resident. The Department reserves the right to review, revise or revoke any and all variances at any time.

Please contact Gail Hansen at (608) 266-2966 or at hansege@dhfs.state.wi.us if you have any questions or need additional clarification.

PDF: The free Acrobat Reader® software is needed to view and print portable document format (PDF) files. Learn more.